Type of Anesthesia May Influence Breast Cancer Recurrence Post-Surgery

In vitro studies demonstrated a reduced incidence of apoptosis in patients administered inhaled anesthetics compared with those administered propofol during surgery.
Published Online: July 14, 2014

New research findings by University College Dublin scientists published in the British Journal of Anaesthesia indicate that the type of anaesthetic used during surgery could affect the metastatic potential of cancer cells - that is their ability to spread to other parts of the body.

To conduct the research, the scientists took blood before and after surgery from breast cancer patients who had been given different types of anaesthetic and pain relief. Some of the women had used standard inhaled general anaesthetics with morphine based pain relief*(2), and others had been anaesthetised using regional (breast numbing) techniques with a single intravenous general anaesthetic called propofol to minimize morphine dosing*(3). In laboratory conditions, breast cancer cells were then exposed to these blood samples.

The scientists found that the blood from patients who had been given standard inhaled general anaesthetics with morphine pain relief reduced a process known as “apoptosis” whereby the body’s cells naturally die off. “Apoptosis” is crucial to preventing the metastatic spread of cancer. In contrast, cancer cells exposed to blood from patients who had been given regional anaesthesia and propofol showed a higher rate of apoptosis, or natural death of cancer cells.

Press release: http://bit.ly/1yi1UfC

Source: University College Dublin



Feature
Recommended Articles
The deal combines Humana's 3.2 million Medicare enrollees with Aetna's 1.26 million Medicare enrollees, giving the new combined company a strong position as the baby boomer population ages.
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Metastatic colorectal cancer patients with higher body mass index (BMI) outlived patients with the lowest BMI by an average of 2-and-a-half months, according to new data presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer 2015.